EAM
Exome Asset Management Portfolio holdings
AUM
$110M
This Quarter Return
+11.92%
1 Year Return
+24.83%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$148M
AUM Growth
+$148M
(+32%)
Cap. Flow
+$29.1M
Cap. Flow
% of AUM
19.64%
Top 10 Holdings %
Top 10 Hldgs %
35.62%
Holding
82
New
30
Increased
14
Reduced
8
Closed
23
Top Buys
| 1 |
Structure Therapeutics
GPCR
|
$5.27M |
| 2 |
Align Technology
ALGN
|
$4.76M |
| 3 |
Gilead Sciences
GILD
|
$4.19M |
| 4 |
Geron
GERN
|
$4.11M |
| 5 |
BioNTech
BNTX
|
$4.1M |
Top Sells
| 1 |
Sarepta Therapeutics
SRPT
|
$5.2M |
| 2 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$4.02M |
| 3 |
Corbus Pharmaceuticals
CRBP
|
$3.84M |
| 4 |
Travere Therapeutics
TVTX
|
$3.64M |
| 5 |
Madrigal Pharmaceuticals
MDGL
|
$3.03M |
Sector Composition
| 1 | Healthcare | 98.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Eli Lilly
LLY
$657B
| $9.26M | 6.26% | 10,447 +747 | +8% | +$662K |
|
2
Ascendis Pharma
ASND
$11.8B
| $6.55M | 4.43% | 43,849 +23,849 | +119% | +$3.56M |
|
3
BridgeBio Pharma
BBIO
$9.89B
| $5.37M | 3.63% | 211,000 +132,093 | +167% | +$3.36M |
|
|
4
Structure Therapeutics
GPCR
$1.11B
| $5.27M | 3.57% | +120,165 | New | +$5.27M |
|
5
TG Therapeutics
TGTX
$4.65B
| $4.86M | 3.28% | 207,627 -43,973 | -17% | -$1.03M |
|
|
6
Align Technology
ALGN
$10.3B
| $4.76M | 3.21% | +18,700 | New | +$4.76M |
|
7
Cigna
CI
$80.3B
| $4.23M | 2.86% | 12,200 | – | – |
|
|
8
Gilead Sciences
GILD
$140B
| $4.19M | 2.83% | +50,000 | New | +$4.19M |
|
|
9
Geron
GERN
$893M
| $4.11M | 2.78% | +905,126 | New | +$4.11M |
|
|
10
BioNTech
BNTX
$24B
| $4.1M | 2.77% | +34,552 | New | +$4.1M |
|
11
Bristol-Myers Squibb
BMY
$96B
| $4.04M | 2.73% | +78,000 | New | +$4.04M |
|
12
Viridian Therapeutics
VRDN
$1.5B
| $3.97M | 2.68% | +174,400 | New | +$3.97M |
|
13
Intuitive Surgical
ISRG
$170B
| $3.65M | 2.47% | 7,427 +1,069 | +17% | +$525K |
|
|
ONC
14
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $3.44M | 2.32% | 15,300 -17,900 | -54% | -$4.02M |
|
|
BPMC
15
DELISTED
Blueprint Medicines
BPMC
| $3.39M | 2.29% | +36,700 | New | +$3.39M |
|
16
Glaukos
GKOS
$5.5B
| $3.37M | 2.28% | +25,857 | New | +$3.37M |
|
|
SWTX
17
DELISTED
SpringWorks Therapeutics
SWTX
| $3.23M | 2.18% | +100,700 | New | +$3.23M |
|
18
Disc Medicine
IRON
$2.07B
| $3.17M | 2.14% | 64,516 +3,516 | +6% | +$173K |
|
19
Cytokinetics
CYTK
$4.23B
| $3.09M | 2.09% | +58,583 | New | +$3.09M |
|
20
Agios Pharmaceuticals
AGIO
$2.19B
| $2.94M | 1.99% | +66,200 | New | +$2.94M |
|
21
Relay Therapeutics
RLAY
$619M
| $2.94M | 1.98% | +414,629 | New | +$2.94M |
|
22
Apellis Pharmaceuticals
APLS
$3.48B
| $2.89M | 1.96% | 100,367 +53,467 | +114% | +$1.54M |
|
23
Dr. Reddy's Laboratories
RDY
$11.8B
| $2.88M | 1.95% | 36,300 | – | – |
|
24
Natera
NTRA
$23.1B
| $2.85M | 1.93% | 22,450 +3,800 | +20% | +$482K |
|
25
Biogen
BIIB
$19.4B
| $2.57M | 1.74% | +13,317 | New | +$2.57M |
|